Mr. Christopher Moreau reports

ALGERNON PHARMACEUTICALS COMPLETES NAME CHANGE TO ALGERNON HEALTH

Algernon Pharmaceuticals Inc. has completed its previously announced name change to Algernon Health Inc. The company's common shares will begin trading under the new name on the Canadian Securities Exchange at market open on Monday, Oct. 20, 2025. The common shares will trade under the new name with a new Cusip number, but the stock symbol will remain the same.

In connection with the name change, the following new Cusip number (01559C106) and ISIN (international securities identification number) (CA01559C1068) have been assigned to the common shares of the company. No action is required to be taken by the shareholders with respect to the name change.

This name changeover on the company's website, in its digital marketing and social media materials and links, and in its URL and company e-mail addresses will be changed on a rolling basis over a short window of time as files and platforms are updated and refreshed across various networks and platforms.

The name change reflects the company's recent announcement that it will be focusing on the Alzheimer's disease (AD) diagnostic market, with plans to establish specialized neuroimaging clinics across North America as its lead program. The clinics will feature the latest technology of U.S. FDA-cleared (U.S. Food and Drug Administration), optimized brain-specific positron emission tomography (PET) scanning systems to detect amyloid plaques in patients, providing significantly lower radiation compared with standard PET/CT (computed tomography) machines currently in operation globally. The PET scans are covered by Medicare, Medicaid and private insurance.

The company recently announced that it had signed a definitive equipment order and financing agreement with Catalyst MedTech for the provision of four Oncovision CareMiBrain brain-specific PET scanner systems to be utilized in four planned Algernon neuroimaging medical clinics. This represents a non-dilutive deal value of over $4-million and includes an agreement to acquire an additional six systems for the establishment of additional clinics, on an adjusted-cost basis.

"Our change in name is an important step in the execution of our new health care initiative to establish and operate dedicated neuroimaging clinics for the early-stage detection of Alzheimer's disease," said Christopher J. Moreau, chief executive officer of Algernon Health. "It underscores our commitment as an evolving, consumer-facing brand providing health care solutions to patients in need."

Algernon continues to be the parent company of a private subsidiary called Algernon NeuroScience, which has been advancing a psychedelic program investigating a proprietary form of DMT (N,N-dimethyltryptamine) for stroke and traumatic brain injury recovery. The company also owns a 20-per-cent equity position in Seyltx, a private U.S.-based drug development company advancing a chronic cough drug called ifenprodil.

About Algernon Pharmaceuticals Inc.

Algernon is a Canadian health care company focused on the provision of brain-specific PET scanning services through a planned network of new clinics in North America for the early-stage detection of Alzheimer's disease as well as other forms of dementia, epilepsy, neuro-oncology and movement disorders. Algernon is also the parent company of a private subsidiary called Algernon NeuroScience, which has been advancing a psychedelic program investigating a proprietary form of DMT for stroke and traumatic brain injury recovery. The company also owns a 20-per-cent equity position in Seyltx, a private U.S.-based drug development company advancing a chronic cough drug called ifenprodil.

We seek Safe Harbor.